Moreno A, Serrano V, Casado J L, Arenas C, Alberca R
Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla.
Neurologia. 1995 Feb;10(2):76-80.
Double-blind studies have demonstrated the efficacy of sumatriptan for the treatment of cluster headache (CH) but little is known about its use on a daily basis. The open trial reported here analyzed the efficacy, tolerance and appropriateness of subcutaneous administration of sumatriptan; the results are compared with findings for other treatments of CH. Sumatriptan was used in 232 attacks suffered by 16 patients and its effect was very rapid. Pain began to diminish a mean 9 minutes after injection and the most intense had disappeared in less than 15 minutes. All the patients preferred sumatriptan to other treatments. No serious side effects were recorded and the patients were satisfied with subcutaneous injection. Sumatriptan was considered the first choice medication for treatment of CH symptoms, although its high cost is a drawback that had to be taken into account.
双盲研究已证明舒马曲坦治疗丛集性头痛(CH)的疗效,但对于其日常使用情况了解甚少。本文报告的开放试验分析了皮下注射舒马曲坦的疗效、耐受性和适用性;并将结果与CH的其他治疗方法的研究结果进行比较。16例患者的232次发作使用了舒马曲坦,其效果非常迅速。注射后平均9分钟疼痛开始减轻,不到15分钟最剧烈的疼痛就消失了。所有患者都更喜欢舒马曲坦而非其他治疗方法。未记录到严重副作用,患者对皮下注射感到满意。舒马曲坦被认为是治疗CH症状的首选药物,尽管其高昂的成本是一个必须考虑的缺点。